{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:41:09Z","timestamp":1792615269392,"version":"4.5.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2024-0372"],"award-info":[{"award-number":["FO2024-0372"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007453","name":"Stiftung VERUM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00263612"],"award-info":[{"award-number":["RS-2023-00263612"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["AF-1011738"],"award-info":[{"award-number":["AF-1011738"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017018","name":"Wallenberg Centre for Molecular and Translational Medicine","doi-asserted-by":"publisher","award":["KAW2023.0371"],"award-info":[{"award-number":["KAW2023.0371"]}],"id":[{"id":"10.13039\/501100017018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017018","name":"Wallenberg Centre for Molecular and Translational Medicine","doi-asserted-by":"publisher","award":["KAW2014.0363"],"award-info":[{"award-number":["KAW2014.0363"]}],"id":[{"id":"10.13039\/501100017018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2145 SyNergy \\u2013 ID 390857198"],"award-info":[{"award-number":["EXC 2145 SyNergy \\u2013 ID 390857198"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023336","name":"Vogel Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005224","name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["101253010"],"award-info":[{"award-number":["101253010"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["101132356"],"award-info":[{"award-number":["101132356"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR203321"],"award-info":[{"award-number":["NIHR203321"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG081394-01"],"award-info":[{"award-number":["R01 AG081394-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021066","name":"Gates Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005760","name":"G\u00f6teborgs Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2023-06188"],"award-info":[{"award-number":["2023-06188"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-06545"],"award-info":[{"award-number":["2021-06545"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007212","name":"V\u00e4stra G\u00f6talandsregionen","doi-asserted-by":"publisher","award":["VGFOUREG-995510"],"award-info":[{"award-number":["VGFOUREG-995510"]}],"id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuron"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neuron.2026.09.006","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:59:42Z","timestamp":1792508382000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["More than just accuracy: A pathway-level framework for implementing blood and digital biomarkers for Alzheimer\u2019s disease care"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1981-7435","authenticated-orcid":false,"given":"Robert","family":"Perneczky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-6240","authenticated-orcid":false,"given":"Boris-Stephan","family":"Rauchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuron.2026.09.006_bib1","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.2024.13855","article-title":"Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care","volume":"332","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.neuron.2026.09.006_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14201","article-title":"Clinical use of biomarkers in the era of Alzheimer's disease treatments","volume":"21","author":"VandeVrede","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib4","unstructured":"US Food and Drug Administration. About Biomarkers and Qualification. https:\/\/www.fda.gov\/drugs\/biomarker-qualification-program\/about-biomarkers-and-qualification#what-is."},{"key":"10.1016\/j.neuron.2026.09.006_bib5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.neuron.2026.09.006_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuron.2026.09.006_bib7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02815140","article-title":"Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?","volume":"26","author":"Blennow","year":"1995","journal-title":"Mol. Chem. Neuropathol."},{"key":"10.1016\/j.neuron.2026.09.006_bib8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ana.410380413","article-title":"Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease","volume":"38","author":"Motter","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib10","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2967\/jnumed.124.268756","article-title":"Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup","volume":"66","author":"Rabinovici","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.neuron.2026.09.006_bib11","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamaneurol.2025.2218","article-title":"Concordance Between Amyloid-PET Quantification and Real-World Visual Reads","volume":"82","author":"Zeltzer","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib13","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barth\u00e9lemy","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2026.09.006_bib14","article-title":"Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings","volume":"21","author":"Palmqvist","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib16","doi-asserted-by":"crossref","DOI":"10.2196\/65297","article-title":"Smartphone- and Tablet-Based Tools to Assess Cognition in Individuals With Preclinical Alzheimer Disease and Mild Cognitive Impairment: Scoping Review","volume":"27","author":"van den Berg","year":"2025","journal-title":"J. Med. Internet Res."},{"key":"10.1016\/j.neuron.2026.09.006_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-022-01117-1","article-title":"The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review","volume":"14","author":"Brand","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuron.2026.09.006_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100455","article-title":"Plasma A\u03b242\/40 predicts progression from A\u03b2-amyloid negative to positive PET scans","volume":"13","author":"Feizpour","year":"2026","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.neuron.2026.09.006_bib19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2026.09.006_bib20","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1002\/alz.14315","article-title":"Head-to-head comparison of leading blood tests for Alzheimer's disease pathology","volume":"20","author":"Schindler","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib21","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s43587-025-00951-w","article-title":"Plasma tau biomarkers for biological staging of Alzheimer's disease","volume":"5","author":"Montoliu-Gaya","year":"2025","journal-title":"Nat Aging"},{"key":"10.1016\/j.neuron.2026.09.006_bib22","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2536792123","article-title":"Head-to-head comparison of brain-derived pTau217 and total pTau217 for brain amyloid and tau pathology classification","volume":"123","author":"Jiang","year":"2026","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2026.09.006_bib23","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease","volume":"31","author":"Horie","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2026.09.006_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100056","article-title":"Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use","volume":"12","author":"Sch\u00f6ll","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.neuron.2026.09.006_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-025-00846-9","article-title":"Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases","volume":"20","author":"Youn","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuron.2026.09.006_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41586-025-10018-w","article-title":"Biofluid biomarkers in Alzheimer's disease and other neurodegenerative dementias","volume":"650","author":"Zetterberg","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.neuron.2026.09.006_bib27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41582-026-01215-w","article-title":"Plasma biomarkers for Alzheimer disease: the road from laboratory results to clinical practice","volume":"22","author":"Teunissen","year":"2026","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70483","article-title":"Alzheimer's disease and its co-pathologies: Implications for hippocampal degeneration, cognitive decline, and the role of APOE epsilon4","volume":"21","author":"Gawor","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib29","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","article-title":"Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid","volume":"18","author":"Concha-Marambio","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.neuron.2026.09.006_bib30","unstructured":"ALZFORUM. (2026). Acetylated Tau, a Marker for \u2026 TDP-43 Pathology? https:\/\/www.alzforum.org\/news\/research-news\/acetylated-tau-marker-tdp-43-pathology."},{"key":"10.1016\/j.neuron.2026.09.006_bib31","article-title":"Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer's Disease","volume":"11","author":"Agnello","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.neuron.2026.09.006_bib32","unstructured":"FDA. (2025) FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease."},{"key":"10.1016\/j.neuron.2026.09.006_bib33","unstructured":"Roche. (2025) Roche\u2019s Elecsys\u00ae pTau181 Becomes the Only FDA-Cleared Blood Test for Use in Primary Care to Rule Out Alzheimer\u2019s-Related Amyloid Pathology. https:\/\/www.roche.com\/investors\/updates\/inv-update-2025-10-13b."},{"key":"10.1016\/j.neuron.2026.09.006_bib34","unstructured":"Roche. (2025). Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer\u2019s disease. https:\/\/www.roche.com\/media\/releases\/med-cor-2025-07-23b."},{"key":"10.1016\/j.neuron.2026.09.006_bib47","unstructured":"ARUP Consult. Choose the Right Test with ARUP Consult. https:\/\/arupconsult.com\/."},{"key":"10.1016\/j.neuron.2026.09.006_bib35","article-title":"Independent validation of the PrecivityAD2(\u2122) blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment","author":"Coppinger","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.neuron.2026.09.006_bib36","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2025.3217","article-title":"Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease","volume":"82","author":"Salvad\u00f3","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70469","article-title":"Comparison of plasma p-tau217\/A\u03b242, p-tau217, and A\u03b242\/A\u03b240 biomarkers by race to detect Alzheimer's disease","volume":"21","author":"Cousins","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib38","article-title":"Diagnostic accuracy of plasma p-tau217\/A\u03b242 for Alzheimer's disease in clinical and community cohorts","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70793","article-title":"Multivariate models using NULISAseq and plasma p-tau217 for staging Alzheimer's disease","volume":"21","author":"Doecke","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14502","article-title":"Clinical utility of plasma p-tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease","volume":"21","author":"Chong","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib41","article-title":"Cross-cultural validation of plasma p-tau217 and p-tau181 as precision biomarkers for amyloid PET positivity: An East Asian study in Taiwan and Korea","volume":"21","author":"Lin","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib42","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00259-025-07457-y","article-title":"Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles","volume":"53","author":"Shin","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neuron.2026.09.006_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70916","article-title":"Cross-cohort validation and cutpoint estimation of the Janssen plasma p-tau217+ assay in predominantly cognitively normal community studies","volume":"21","author":"Balogun","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib44","article-title":"Alzheimer's disease biological PET staging using plasma p217+tau","volume":"5","author":"Feizpour","year":"2025","journal-title":"Commun. Med. (Lond)"},{"key":"10.1016\/j.neuron.2026.09.006_bib45","unstructured":"ALZpath. (2025). ALZpath and Siemens Healthineers sign licensing agreement to advance global access to blood-based Alzheimer\u2019s disease diagnostic testing. https:\/\/alzpath.bio\/alzpath-and-siemens-healthineers-sign-licensing-agreement-to-advance-global-access-to-blood-based-alzheimers-disease-diagnostic-testing\/."},{"key":"10.1016\/j.neuron.2026.09.006_bib46","unstructured":"Beckman Coulter. (2025). Beckman Coulter receives FDA breakthrough device designation for Alzheimer\u2019s disease blood test. https:\/\/www.beckmancoulter.com\/about-beckman-coulter\/newsroom\/press-releases\/2025\/q1\/2025-jan28-bec-receives-fda-breakthrough-device-designation."},{"key":"10.1016\/j.neuron.2026.09.006_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/alz.082874","article-title":"Quantitative Amyloid-PET in Real-World Practice: Lessons from the Imaging Dementia\u2014Evidence for Amyloid Scanning (IDEAS) study","volume":"19","author":"La Joie","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib49","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S1474-4422(25)00227-3","article-title":"Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"24","author":"Therriault","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib50","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100094","article-title":"Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics","volume":"12","author":"Villain","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.neuron.2026.09.006_bib52","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41582-024-00989-1","article-title":"Alzheimer disease blood biomarkers: considerations for population-level use","volume":"20","author":"Mielke","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-084781","article-title":"Evidence gap in blood biomarkers for Alzheimer's disease","volume":"390","author":"Van Gool","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.neuron.2026.09.006_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanhl.2024.07.013","article-title":"Challenges in the practical implementation of blood biomarkers for Alzheimer's disease","volume":"5","author":"Sch\u00f6ll","year":"2024","journal-title":"Lancet Healthy Longev."},{"key":"10.1016\/j.neuron.2026.09.006_bib55","article-title":"How can Alzheimer's disease blood-based biomarkers reach clinical practice?","volume":"17","author":"Perneczky","year":"2025","journal-title":"Alzheimers Dement. (Amst)"},{"key":"10.1016\/j.neuron.2026.09.006_bib56","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70752","article-title":"Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium","volume":"21","author":"Verberk","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib58","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/alz.12510","article-title":"Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group","volume":"18","author":"Verberk","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib59","article-title":"Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology","volume":"15","author":"Sunde","year":"2023","journal-title":"Alzheimers Dement. (Amst)"},{"key":"10.1016\/j.neuron.2026.09.006_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/biom12091194","article-title":"Head-to-Head Comparison of Different Blood Collecting Tubes for Quantification of Alzheimer's Disease Biomarkers in Plasma","volume":"12","author":"Jiang","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuron.2026.09.006_bib61","unstructured":"Association for Diagnostics and Laboratory Medicine. (2020). AACC Guidance Document on Biotin Interference in Laboratory Tests. https:\/\/myadlm.org\/science-and-research\/academy-guidance\/biotin-interference-in-laboratory-tests."},{"key":"10.1016\/j.neuron.2026.09.006_bib62","unstructured":"ALZFORUM. (2025). Trouble with Fujirebio\u2019s FDA-Cleared Blood Test? Or a Lousy Lot? https:\/\/www.alzforum.org\/news\/conference-coverage\/trouble-fujirebios-fda-cleared-blood-test-or-lousy-lot."},{"key":"10.1016\/j.neuron.2026.09.006_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14508","article-title":"The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study","volume":"21","author":"Ashton","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib64","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00406-023-01751-2","article-title":"Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer's disease","volume":"275","author":"Morgado","year":"2025","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuron.2026.09.006_bib65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13195-026-01979-9","article-title":"Real-world diagnostic performance of blood-based biomarkers for Alzheimer's disease: robust performance except after stroke and high charlson comorbidity index","volume":"18","author":"Vigneswaran","year":"2026","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuron.2026.09.006_bib66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2023.4719","article-title":"Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial","volume":"81","author":"Brum","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib67","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.neuron.2026.09.006_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70411","article-title":"Multimorbidity patterns and blood biomarkers of Alzheimer's disease in community-dwelling cognitively unimpaired older adults","volume":"21","author":"Marengoni","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib69","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1212\/WNL.0000000000207419","article-title":"Association of Chronic Kidney Disease With Plasma NfL and Other Biomarkers of Neurodegeneration: The H70 Birth Cohort Study in Gothenburg","volume":"101","author":"Dittrich","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2026.09.006_bib70","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-025-04130-2","article-title":"Plasma concentrations of neurofilament light, p-Tau231 and glial fibrillary acidic protein are elevated in patients with chronic kidney disease and correlate with measured glomerular filtration rate","volume":"26","author":"Axelsson","year":"2025","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.neuron.2026.09.006_bib71","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2026.09.006_bib72","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210287","article-title":"Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations","volume":"104","author":"Bornhorst","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2026.09.006_bib73","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","article-title":"Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios","volume":"80","author":"Janelidze","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70765","article-title":"Body mass index and blood volume influence plasma biomarkers and positron emission tomography classification in preclinical Alzheimer's disease","volume":"21","author":"Jacobs","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib75","article-title":"Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease","volume":"17","author":"Mohammadi","year":"2025","journal-title":"Alzheimers Dement. (Amst)"},{"key":"10.1016\/j.neuron.2026.09.006_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70381","article-title":"Plasma NfL and GFAP for predicting VCI and related brain changes in community and clinical cohorts","volume":"21","author":"Raghavan","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib77","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41582-025-01071-0","article-title":"Alzheimer disease seen through the lens of sex and gender","volume":"21","author":"Castro-Aldrete","year":"2025","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib78","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer's disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2026.09.006_bib79","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000545717","article-title":"Sex Differences in Biofluid Biomarkers for Alzheimer's Disease","volume":"25","author":"Aksnes","year":"2025","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neuron.2026.09.006_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-49859-w","article-title":"Baseline levels and longitudinal changes in plasma A\u03b242\/40 among Black and white individuals","volume":"15","author":"Xiong","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuron.2026.09.006_bib81","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1212\/WNL.0000000000200358","article-title":"Effect of Race on Prediction of Brain Amyloidosis by Plasma A\u03b242\/A\u03b240, Phosphorylated Tau, and Neurofilament Light","volume":"99","author":"Schindler","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2026.09.006_bib82","article-title":"Plasma biomarkers, brain amyloid-beta pathology, and cortical thickness in a non-Hispanic White and Black\/African American middle-aged community cohort: The HCP-CoBRA study","volume":"21","author":"Brodman","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib83","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/acn3.51529","article-title":"Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease","volume":"9","author":"Brickman","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib84","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/alz.13722","article-title":"The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease","volume":"20","author":"Mohs","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119876","article-title":"Exploring the effect of APOE \u03b54 on biomarkers of neurodegeneration in Alzheimer's disease","volume":"562","author":"Agnello","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.neuron.2026.09.006_bib86","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.neuron.2026.09.006_bib87","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/acn3.51676","article-title":"Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface","volume":"9","author":"Vermunt","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib88","unstructured":"EMA. (2025) Concept Paper on the Need for Revision of the Guideline on the Clinical Investigation of Medicines for the Treatment of Alzheimer\u2019s Disease. EMA\/231314\/2025; Public Consultation Opened Aug 6, 2025."},{"key":"10.1016\/j.neuron.2026.09.006_bib89","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/alz.71181","article-title":"Associations between accelerometer-derived physical activity complexity, cognitive function, and plasma biomarkers of Alzheimer's disease","volume":"22","author":"Cai","year":"2026","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70753","article-title":"Validation status of cognitive digital assessments by the FDA BEST framework and context of use in preclinical AD studies: A systematic review","volume":"21","author":"Porta-Mas","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib91","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3233\/JAD-170896","article-title":"Comparing the Electronic and Standard Versions of the Montreal Cognitive Assessment in an Outpatient Memory Disorders Clinic: A Validation Study","volume":"62","author":"Berg","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuron.2026.09.006_bib92","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.33786","article-title":"Evaluation of the Electronic Clinical Dementia Rating for Dementia Screening","volume":"6","author":"Nosheny","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.neuron.2026.09.006_bib93","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1111\/jgs.18902","article-title":"Montreal Cognitive Assessment (MoCA) XpressO: Validation of a digital self-administered cognitive prescreening tool","volume":"72","author":"Klil-Drori","year":"2024","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.neuron.2026.09.006_bib94","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-021-00470-z","article-title":"Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study","volume":"4","author":"Meier","year":"2021","journal-title":"NPJ Digit. Med."},{"key":"10.1016\/j.neuron.2026.09.006_bib95","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/arclin\/acu068","article-title":"Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Abeta accumulation in cognitively normal older adults and adults with MCI","volume":"30","author":"Lim","year":"2015","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.neuron.2026.09.006_bib96","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1038\/s41591-025-03965-4","article-title":"Primary care detection of Alzheimer's disease using a self-administered digital cognitive test and blood biomarkers","volume":"31","author":"Tideman","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2026.09.006_bib97","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1017\/S135561772200042X","article-title":"Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer's disease","volume":"29","author":"Nicosia","year":"2023","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.neuron.2026.09.006_bib98","doi-asserted-by":"crossref","DOI":"10.1007\/s00406-026-02347-2","article-title":"Diagnostic accuracy of a self-administered digital cognitive test battery for differentiating early Alzheimer's disease from controls","author":"Rutt","year":"2026","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuron.2026.09.006_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-024-00999-9","article-title":"A remote digital memory composite to detect cognitive impairment in memory clinic samples in unsupervised settings using mobile devices","volume":"7","author":"Berron","year":"2024","journal-title":"NPJ Digit. Med."},{"key":"10.1016\/j.neuron.2026.09.006_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-025-01583-5","article-title":"A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer's disease","volume":"8","author":"Polk","year":"2025","journal-title":"NPJ Digit. Med."},{"key":"10.1016\/j.neuron.2026.09.006_bib102","article-title":"Current advances in digital cognitive assessment for preclinical Alzheimer's disease","volume":"13","author":"\u00d6hman","year":"2021","journal-title":"Alzheimers Dement. (Amst)"},{"key":"10.1016\/j.neuron.2026.09.006_bib104","doi-asserted-by":"crossref","DOI":"10.1177\/14604582251387656","article-title":"Navigating through regulatory frameworks for digital therapeutics and biomarkers","volume":"31","author":"Koller","year":"2025","journal-title":"Health Inform. J."},{"key":"10.1016\/j.neuron.2026.09.006_bib105","article-title":"Medical Device Coordination Group: Guidance on Qualification and Classification of Software in Regulation (EU) 2017\/745 \u2013 MDR and Regulation (EU) 2017\/746 \u2013 IVDR","volume":"2019","year":"2025","journal-title":"MDCG"},{"key":"10.1016\/j.neuron.2026.09.006_bib103","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70966","article-title":"Acceptable standards for clinic-based digital cognitive assessments: Recommendations from the Global CEO Initiative on Alzheimer's Disease","volume":"21","author":"Thompson","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib106","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1002\/alz.13919","article-title":"Remote and unsupervised digital memory assessments can reliably detect cognitive impairment in Alzheimer's disease","volume":"20","author":"Berron","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib107","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1002\/alz.14219","article-title":"REAL AD-Validation of a realistic screening approach for early Alzheimer's disease","volume":"20","author":"Leuzy","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib108","unstructured":"Kneu Health. https:\/\/kneuhealth.com\/."},{"key":"10.1016\/j.neuron.2026.09.006_bib109","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s44400-026-00060-4","article-title":"An ethical framework for the clinical use of Alzheimer\u2019s disease biomarker testing. npj","volume":"2","author":"Scipion","year":"2026","journal-title":"Dementia"},{"key":"10.1016\/j.neuron.2026.09.006_bib111","doi-asserted-by":"crossref","first-page":"155","DOI":"10.14283\/jpad.2023.94","article-title":"Estimates of Current Capacity for Diagnosing Alzheimer's Disease in Sweden and the Need to Expand Specialist Numbers","volume":"11","author":"Mattke","year":"2024","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.neuron.2026.09.006_bib112","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/13558196231211141","article-title":"Expected wait times for access to a disease-modifying Alzheimer's treatment in England: A modelling study","volume":"29","author":"Mattke","year":"2024","journal-title":"J. Health Serv. Res. Policy"},{"key":"10.1016\/j.neuron.2026.09.006_bib116","article-title":"Performing multiple biomarker tests delays initiation of amyloid-targeting treatments","volume":"18","author":"Hofmann","year":"2026","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2026.09.006_bib113","unstructured":"Alzheimer's Research UK. (2025). UK trial launches to transform Alzheimer\u2019s diagnosis with simple blood test. https:\/\/www.alzheimersresearchuk.org\/news\/uk-trial-launches-to-transform-alzheimers-diagnosis-with-simple-blood-test\/."},{"key":"10.1016\/j.neuron.2026.09.006_bib114","doi-asserted-by":"crossref","DOI":"10.1177\/08919887261429558","article-title":"Motivation, Worries and Digital Affinity in Cognitive Screening - Qualitative Findings From the CogScreen Study","author":"Tegethoff","year":"2026","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.neuron.2026.09.006_bib115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.14283\/jpad.2024.32","article-title":"Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer\u2019s Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project: The AD-RIDDLE Project","volume":"11","author":"Malzbender","year":"2024","journal-title":"J. Prev. Alzheimers. Dis."}],"container-title":["Neuron"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896627326006896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896627326006896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:51:35Z","timestamp":1792612295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896627326006896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":115,"alternative-id":["S0896627326006896"],"URL":"https:\/\/doi.org\/10.1016\/j.neuron.2026.09.006","relation":{},"ISSN":["0896-6273"],"issn-type":[{"value":"0896-6273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"More than just accuracy: A pathway-level framework for implementing blood and digital biomarkers for Alzheimer\u2019s disease care","name":"articletitle","label":"Article Title"},{"value":"Neuron","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuron.2026.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}